136 Hikma PHarmaceuticals Plc annual report 2011 notes to the consolidated financialstatements Continued 36. share-based payments equity-settled share option scheme During the year ended 31 December 2011, the company had one stock option compensation scheme settled by equity instruments, with four separate grant dates.
the options over these instruments are settled in equity once exercised.
Details of the grants under the scheme are shown below: The estimated fair value of The share each share price at exercise number option granted grant date price expected expected expected average risk-free date of grants granted usd usd usd volatility dividend yield contractual life interest rate 4 november 2008 85,000 1.14 5.45 5.45 34.90% 1.21% 4.0 years 4.11% 29 april 2008 1,041,500 2.61 9.19 9.19 31.50% 0.08% 3.8 years 4.54% 13 october 2005 1,600,000 0.74 4.50 4.50 26.20% 6.67% 7.5 years 4.54% 12 october 2004 9,520,000 0.35 0.91 0.91 44.80% 3.85% 7.5 years 4.22% all the general employees share option plans have a ten year contractual life and vesting conditions of 20% per year for five years beginning on the first anniversary of the grant date.
the estimated fair value of each share option granted in the general employee share option plans was calculated by applying a binomial option pricing model.
it was assumed that each option tranche will be exercised immediately after the vesting date.
further details of the general employee share option plan are as follows: 2011 2010 weighted weighted number of average exercise number of average exercise shares option price in usd shares option price in usd outstanding at 1 january 2,382,618 3.33 3,645,700 3.42 exercised during the year 1,634,318 1.55 1,189,382 3.25 expired during the year 5,100 5.45 73,700 9.18 outstanding at 31 december 743,200 7.24 2,382,618 3.33 exercisable at 31 december 433,000 6.06 1,900,218 1.96 the cost of the equity-settled share option scheme of usD 296,000 2010: usD 403,000 has been recorded in the consolidated statement of comprehensive income as part of general and administrative expenses.
the weighted average share price at the date of exercise for share options exercised during the year was usD 11.90. the options outstanding at 31 December 2011 had a weighted average remaining contractual life of less than one year.
expected volatility was determined by calculating the historical volatility of the Groups share price over the previous three to four years.
long-term incentive plan During the year ended 31 December 2011 the company had two long-term incentive plans ltiP settled by equity instruments, with eight separate grant dates.
under the ltiP, conditional awards and nil cost options are granted which vest after three years subject to a total shareholder return tsr performance condition.
this condition measures the Groups tsr relative to a comparator group of other pharmaceutical companies.
in this case, the vesting schedule dictates that 20% of awards vest for median performance and 100% for upper quartile performance, with pro-rata vesting in between these points.
no awards vest for performance which is below the median.
for awards made from 2010 the tsr condition applies in respect of 50% of the award and financial metrics apply in respect of the remaining 50%.
for further details see the remuneration committee report.
